ProPhase Labs, Inc. (PRPH): Nasdaq/NYSE listing notice — ProPhase Labs receives Nasdaq bid price deficiency notice; 180-day cure period until June 24, 2025

ProPhase Labs, Inc.

Received Nasdaq letter on Dec 26, 2024 for bid price below $1.00 for 30 consecutive business days.
Has until June 24, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.
Company qualifies for potential second 180-day extension due to stockholders' equity >= $5M.
Failure to regain compliance may lead to delisting from Nasdaq.
Management states they are working to evidence compliance, but no assurance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 26, 2024, ProPhase Labs, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until June 24, 2025, to regain compliance with the minimum bid price requirement. The continued listing standa

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-052297

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.